Toll free

18002022232

Consultant, Hemato-Oncology & Bone Marrow Transplant Physician

Dr. Bilal Kazi

Dr. Bilal Kazi is a Consultant, Hemato-Oncology and Bone Marrow Transplant (BMT) Physician with an extensive experience in cellular therapy and advanced transplant care. He has worked with cutting-edge treatments such as CAR-T and T-cell therapies and has managed numerous patients with complex blood cancers. He has also performed a significant number of successful bone marrow transplants.

Dr. Kazi is skilled in patient preparation, treatment planning, and handling complications, making him well-versed in delivering modern, personalized cancer care. He is experienced in managing treatment-related side effects and has also used advanced antibody therapies as bridging options before cellular treatments in challenging lymphoma cases.

He has trained and served across leading hematology and transplant centres, beginning as a Senior Resident in Clinical Hematology and BMT at Nair Hospital, later advancing to the role of Associate Consultant in Hematology and BMT at Apollo Multispecialty Hospital, Kolkata, Dr. Bilal Kazi remains devoted to improving outcomes, expanding his knowledge, and offering the most up-to-date treatments in hemato-oncology and transplant care.

MBBS – P.D.V.V.P.F Medical College & Hospital, Ahmednagar, Maharashtra, 2008 - 2013

MD – Topiwala National Medical College & B.Y.L. Nair Hospital, Mumbai, Maharashtra, 2015 - 2018

DM (Clinical Hematology) – NRS Medical College & Hospital, Kolkata, West Bengal, 2019 - 2022

  • Senior Resident, Clinical Hematology & BMT – Topiwala National Medical College & B.Y.L Nair Hospital, Mumbai
  • Associate Consultant, Clinical Hematology & BMT – Apollo Multispecialty Hospital, Kolkata
  • Consultant Hemato-Oncologist, Cellular Therapy & BMT Physician – SunAct, Thane

 

Cellular Therapy & Transplant Experience

  • CAR-T Cell Therapy: Hands-on experience with both autologous and allogeneic CAR-T therapies; treated hematologic malignancies (CD19, BCMA) and participated in trials involving CAR-T for solid tumors (e.g., Claudin 18.2).
  • TCR Therapy: Experience with T-cell receptor therapy infusions for solid organ malignancies.
  • Bone Marrow Transplantation (BMT): Performed over 75 autologous and allogeneic transplants for various hematologic conditions.
  1. Borah P, Kazi BS et al. Effect of age, comorbidity and remission status on outcome of COVID-19 in patients with hematological malignancies. Blood Cells Mol Dis. 2021;87:102525.
  2. Kazi BS. An interesting case of Langerhans cell histiocytosis. J Hematol Allied Sci. 2021;1:122–3.
  3. Kazi BS, et al. Pyruvate kinase deficiency case report. J Hematol Allied Sci. 2022;2:99–100.
  4. Kazi BS, Chakrapani A. ASH image: Hemophagocytosis. Published: 04/02/2024.
  5. Kazi BS, et al. Cold agglutinin syndrome from Mycoplasma pneumoniae. J Hematol Allied Sci. 2024;4:46–7.
  6. Bilal K, et al. EBV-induced Warm AIHA. Turk J Haematol. Published: June 28, 2024.
  7. Kazi B, Chakrapani A. Flame cells in IgA Myeloma. Indian J Hematol Blood Transfus. 2024. https://doi.org/10.1007/s12288-024-01819-6
  8. Kazi BS, Chakrapani A. Anaplastic Multiple Myeloma (ASH image). Published: 18/07/2024.
  9. Kazi BS, Shinde SV. Microfilaria in buffy coat (ASH image). Published: 22/07/2024.
  10. Rumani I, et al. Clinicopathological response post-NACT in LABC. J Curr Oncol Trends. 2024;1:54–62.
  11. Kazi B, et al. Eosinophilia masking splenic microfilariasis. Turk J Haematol. 2024;41(4):279–80.
  12. Kazi B, et al. Olanzapine-induced hypertriglyceridemia in cancer care. Curr Probl Cancer: Case Rep. 2024. https://doi.org/10.1016/j.cpccr.2024.100345.
  13. Kazi B, Adallah AO, Patil V, Tembhare P, Rumani I, Kazi MNC. Defying the Odds: Successful Rescue with Teclistamab in a Case of Ultra-High-Risk Relapsed/Refractory Multiple Myeloma Transforming to Secondary Plasma Cell Leukemia Post-BCMA CAR T Failure. Turk J Haematol. Published online July 28, 2025. doi:10.4274/tjh.galenos.2025.2025.0216.
  14. Vairamoorthy N, Kazi B, Patil V. Enhanced CAR T-Cell Therapy for Relapsed Lymphoma. N Engl J Med. 2025;393(6):619-620. doi:10.1056/NEJMc2507794
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct genitourinary cancer case study on GPC3-targeted CAR T therapy for refractory non-seminomatous germ cell tumor
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct colon cancer case study highlighting TCR-based approach in metastatic colon cancer with lung lesions
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct breast cancer case study showcasing HER2-positive treatment with CAR T-cell therapy
SunAct head and neck cancer case study using TCR-p53 therapy in inoperable squamous cell carcinoma
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct case study featuring gamma delta T-cell therapy for recurrent tongue carcinoma with extensive metastasis
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct head and neck cancer case study on salivary ductal carcinoma managed with advanced therapies
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct case study on GD2-targeted CAR T therapy for diffuse midline glioma in a 22-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male
SunAct CNS case study on GBM treatment using multiple gene mutation targeting in a 36-year-old male